Literature DB >> 6221476

[Clinical aspects, course and prognosis of various forms of hypertrophic cardiomyopathy].

H Kuhn, F Gietzen, J Mercier, B Lösse, E Köhler, H D Schulte, W Bircks, F Loogen.   

Abstract

To characterize the different types of hypertrophic cardiomyopathy [typical (subaortic) hypertrophic obstructive cardiomyopathy (HOCM) (n = 235), atypical (midventricular or apical) HOCM (n = 33), and hypertrophic nonobstructive cardiomyopathy (HNCM) (n = 85)], studies of the clinical picture, course, and prognosis were performed in 353 patients. Clinical picture. There were found to be distinct differences between the diseases in terms of incidence, symptoms, findings at auscultation, carotid pulse tracings, ECG (incidence of abnormal negative T-waves), and echocardiography. Echochardiography proved to be diagnostically less specific than invasive methods, however, and in particular often failed to distinguish between atypical HOCM and HNCM. Clinical course. There was no evidence of a change from one form of hypertrophic cardiomyopathy to the other. The Sokolow-Lyon index in the ECG did not increase in any group. The rate of complications (endocarditis, systemic emboli) varied between 0.61 and 1.28 events per 100 patient years. Only 7.4%-23.5% of patients with HOCM improved as a result of conservative treatment, compared to 83%-87.5% of surgical patients. In addition, the rate of postoperative syncope was reduced by 90%. Prognosis. 90 patients were operated on. Operative mortality in typical HOCM was 4.5% over the last 5 years. If this is disregarded, the cumulative survival rates are significantly higher in surgical patients with typical HOCM than in those treated conservatively. The data confirm surgical treatment to be the therapy of choice in patients with HOCM refractory to conservative treatment. The prognosis seems to be improved by operation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221476

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  2 in total

1.  [Transcoronary ablation of septal hypertrophy (TASH): supersedes it the surgery (myectomy)?].

Authors:  H Kuhn; F Gietzen
Journal:  Herz       Date:  1999-12       Impact factor: 1.443

2.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.